FDA’s Final CGT Guidance Brings Clarity
CGT Designation Does Not Mean Shorter Review Time
After issuing a draft version of the guidance on the competitive generic therapy pathway meant to incentivize the development of generics for drugs that lack competition in February 2019, the US FDA has now issued the final guidance that includes several clarifications.
